Lycera Therapeutics' proprietary LAE103 has secured Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of sarcopenic obesity and muscle-related disorders. This marks Lycera's second IND approval in 2025, underscoring its robust independent research and innovation capabilities. The prevalence of sarcopenic obesity is on the rise globally, posing a considerable challenge to the elderly population. LAE103, a monoclonal antibody specifically targeting ActRIIB, is a cornerstone of Lycera's therapeutic portfolio, which also includes two other promising candidates, LAE102 and LAE123. Currently, LAE102 is undergoing Phase I clinical trials in both China and the United States, while LAE123 is in the IND-enabling study phase. Furthermore, Lycera is actively engaged in multiple clinical trials targeting other diseases and is advancing the development of several candidate drugs in the realms of cancer and metabolic disorders.